SAN
DIEGO, Aug. 28, 2024 /PRNewswire/ --
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a
clinical-stage biopharmaceutical company focused on the development
of novel therapies for metabolic and endocrine disorders,
today announced that its chief executive officer, Brian Lian, Ph.D., will be the featured speaker
in a fireside chat at the Morgan Stanley 22nd Annual
Global Healthcare Conference. The conference will take place
September 4-6, 2024, in New York City.
Details are as follows:
- Morgan Stanley 22nd Annual Global Healthcare
Conference
Details: Dr. Lian will participate in a fireside
chat and in 1-on-1 meetings
Conference dates: September 4-6,
2024
Fireside Chat Timing: 1:50 – 2:25
p.m. Eastern on Wednesday, September
4, 2024
Location: New York Marriott Marquis
A live webcast of the fireside chat may be accessed via a link
on the Viking Therapeutics website in the Investors & Media
section under Webcasts. Additionally, a replay of the webcast
will be available on the Viking website following the
conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development of novel first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders, with three compounds currently in clinical
trials. Viking's research and development activities leverage
its expertise in metabolism to develop innovative therapeutics
designed to improve patients' lives. Viking's clinical
programs include VK2735, a novel dual agonist of the glucagon-like
peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide
(GIP) receptors for the potential treatment of various metabolic
disorders. Data from a Phase 1 and a Phase 2 trial evaluating
VK2735 (dosed subcutaneously) for metabolic disorders demonstrated
an encouraging safety and tolerability profile as well as positive
signs of clinical benefit. Concurrently, the company is evaluating
an oral formulation of VK2735 in a Phase 1 trial. Viking is also
developing VK2809, a novel, orally available, small molecule
selective thyroid hormone receptor beta agonist for the treatment
of lipid and metabolic disorders. The compound successfully
achieved both the primary and secondary endpoints in a recently
completed Phase 2b study for the treatment of
biopsy-confirmed non-alcoholic steatohepatitis (NASH) and
fibrosis. In a Phase 2a trial for the treatment of
non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C,
patients who received VK2809 demonstrated statistically significant
reductions in LDL-C and liver fat content compared with patients
who received placebo. The company's newest program is
evaluating a series of internally developed dual amylin and
calcitonin receptor agonists (or DACRAs) for the treatment of
obesity and other metabolic disorders. In the rare disease space,
Viking is developing VK0214, a novel, orally available, small
molecule selective thyroid hormone receptor beta agonist for the
potential treatment of X-linked adrenoleukodystrophy
(X-ALD). VK0214 is currently being evaluated in a
Phase 1b clinical trial in patients with the
adrenomyeloneuropathy (AMN) form of X-ALD.
For more information about Viking Therapeutics, please
visit www.vikingtherapeutics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-at-morgan-stanley-22nd-annual-global-healthcare-conference-302232102.html
SOURCE Viking Therapeutics, Inc.